# Study Evaluating Effect of Esomeprazole, Omeprazole or Lansoprazole on the Pharmacodynamics (PD) and Pharmacokinetics (PK) of Clopidogrel

> **NCT01147588** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 149 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** lansoprazole
- **DRUG:** omeprazole
- **DRUG:** esomeprazole
- **DRUG:** clopidogrel

## Key facts

- **NCT ID:** NCT01147588
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 149 (ACTUAL)
- **Last updated:** 2011-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01147588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01147588, "Study Evaluating Effect of Esomeprazole, Omeprazole or Lansoprazole on the Pharmacodynamics (PD) and Pharmacokinetics (PK) of Clopidogrel". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01147588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*